It is appropriate to speculate that patients with an ALK-positive stage IB NSCLC tumor smaller than 4 cm and concomitant risk factors such as STAS and VPI could also benefit from adjuvant treatment with alectinib. The gene discussed is ALK; the disease is neoplasm.